Overview

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma who were previously untreated with systemic therapy. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Phase:

N/A

Details

Lead Sponsor:

NovoCure GmbH

Collaborator:

Zai Lab (Shanghai) Co., Ltd.

Treatments:

Capecitabine
Oxaliplatin
Trastuzumab